TESTI
Adamo S, Comoglio P, Dolfi A, Molinaro M, Papaccio G, Siracusa G, Stefanini M, Ziparo E (2012) Istologia di V. Monesi, Padova, Piccin
Colombo R - Olmo E (2007) Biologia dei tessuti, Milano, Edi.Ermes
Nelson DL – Cox MM (2006) I principi di biochimica di Lehninger, Bologna, Zanichelli
Spencer JFT - Ragout de Spencer AL (2004) Public Health Microbiology: Methods and Protocols, Totowa (New Jersey), Humana Press
58
REVIEW
Allavena P, Sica A, Solinas G, Porta C, Mantovani A (2007). The inflammatory microenvironment in tumor progression: The role of tumor-associated macrophages. Critical Reviews in Oncology/Hematology 66, 1-9
Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., et al. 2004. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6, 17–32.
Baker JG (2010) The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3- adrenoceptors. Br J Pharmacol 160:1048-1061
Barbieri A, Palma G, Rosati A, Giudice A, Falco A, Petrillo A, Petrillo M, Bimonte S, Di Benedetto M, Esposito G, Stiuso P, Abbruzzese A, Caraglia M, Arra C (2012) Role of endothelial nitric oxide synthase (eNOS) in chronic stress-promoted tumour growth. J Cell Mol Med 16(4):920-6
Bertolotto C (2013) Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica; 2013:635203
Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, et al. (2004a). TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303: 848-8517
Breslow A (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma Ann Surg; 172:902–8
Candelore MR, Deng L, Tota L, Guan XM, Amend A, Liu Y, Newbold R, Cascieri MA, Weber AE (1999) Potent and selective human beta(3)-adrenergic receptor antagonists. J Pharmacol Exp Ther 290:649-655
Calvani M, Pelon F, Comito G, Taddei ML, Moretti S, Innocenti S, Nassini R, Gerlini G, Borgognoni L, Bambi F, Giannoni E, Filippi L, Chiarugi P (2015) Norepinephrine promotes tumor microenvironment reactivity through β3- adrenoreceptors during melanoma progression. Oncotarget; 6:4615-4632
Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., et al. 2001. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7, 575-583.
59
Choi K.S., Bae M.K., Jeong J.W., Moon H.E. and Kim K.W. (2003) Hypoxia- induced angiogenesis during carcinogenesis. J. Biochem. Mol. Biol.; 36: 120-127
Claffey K.P., Shih S.C., Mullen A., Dziennis S., Cusick J.L., et al. 1998. Identification of a human VPF/VEGF 3' untranslated region mediating hypoxia- induced mRNA stability. Mol Biol Cell 9: 469-81
Clark WH Jr (1967) A classification of malignant melanoma in man correlated with histogenesis and biologic behavior In: Montagna W, Hu F, eds. Advances in the biology of the skin, Vol. VIII. New York: Pergamon Press: 621-47
Clark WH Jr, Elder DE, Guerry D 4th, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern AC (1989) Model predicting survival in stage I melanoma based on tumor progression J Natl Cancer Inst; 81:1893-904
Cole SW, Sood AK (2012) Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res; 18:1201-1206
Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1alpha is essential for myeloid cell mediated inflammation. Cell 2003;112(5):645-57
Dal Monte M, Casini G, Filippi L, Nicchia GP, Svelto M, Bagnoli P (2013) Functional involvement of beta3-adrenergic receptors in melanoma growth and vascularization. J Mol Med (Berl) 91:1407- 1419
De Giorgi V, Grazzini M, Gandini S, Benemei S, Lotti T, Marchionni N, Geppetti P (2011) Treatment with beta-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 171:779-781
Dvorak HF, Weaver VM, Tlsty TD, Bergers G (2011). Tumor microenvironment and progression. J Surg Oncol; 103(6):468-74
Elder DE, Gimotty PA, Guerry D (2005) Cutaneous melanoma: estimating survival and recurrence risk based on histopathologic features Dermatol Ther; 18(5):369-85
Fryzek JP, Poulsen AH, Lipworth L, et al. (2006) A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat.; 97(3):231-236
60
Glasner A, Avraham R, Rosenne E, Benish M, Zmora O, Shemer S, Meiboom H, Ben-Eliyahu S (2010) Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta- adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol 184(5):2449-57
Hasegawa H, Saiki I (2002) Psychosocial stress augments tumor development through beta-adrenergic activation in mice. Jpn J Cancer Res. 93(7):729-35
Ji Y, Chen S, Xiao X, Zheng S, Li K (2012) β-blockers: a novel class of antitumor agents. Onco Targets Ther.; 5:391-401
Kalluri R, Zeisberg M (2006). Fibroblasts in cancer. Nat Rev Cancer; 6: 392- 401
Krikun G, Schatz F and Lockwood C J (2004) Endometrial angiogenesis: from physiology to pathology. Ann. NY Acad. Sci.; 1034, 27-35
Kubota, Y., Takubo, K., Shimizu, T., Ohno, H., Kishi, K., Shibuya, M., et al. (2009). M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J. Exp. Med. 206, 1089-1102
Lewis JS, Landers RJ, Underwood JC, Harris AL., Lewis CE. (2000). Expression of vascular endothelial growth factor by macrophages is up regulated in poorly vascularized areas of breast carcinomas. J Pathol; 192: 150-158
Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR (2003) Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer; 98(7):1504-1513.
Michael H Antoni, Susan K Lutgendorf, Steven W Cole, Firdaus S Dhabhar, Sandra E Sephton, Paige Green McDonald, Michael Stefanek, Anil K Sood (2006) The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer; 6(3): 240-248
Michel MC, Cernecka H, Ochodnicky P (2011) Desirable properties of β3- adrenoceptor agonists: implications for the selection of drug development candidates. Eur J Pharmacol 657:1-3
Moretti S, Massi D, Farini V, Baroni G, Parri M, Innocenti S, Cecchi R, Chiarugi P (2013) beta- adrenoceptors are upregulated in human melanoma and
61
their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines. Lab Invest; 93:279-290
Nilsson I, Rolny C, Wu Y, Pytowski B, Hicklin D, Alitalo K, et al. (2004). Vascular endothelial growth factor receptor-3 in hypoxia-induced vascular development. FASEB J.
18-15071515
O’Sullivan C, Lewis CE, Harris AL, Mc Gee JO. (1993). Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet; 342: 148-149
Oguma K, Oshima H, Aoki M, Uchio R, Naka K, Nakamura S, et al. (2008). Activated macrophages promote Wnt signalling through tumour necrosis factor- alpha in gastric tumour cells. EMBO J. 27, 1671-1681
Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR (1999). Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59, 5002–5011.
Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., et al. 2005. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335–348
Perron L, Bairati I, Harel F, Meyer F (2004) Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control; 15(6):535-541.
Rohrer DK, Chruscinski A, Schauble EH, Bernstein D, Kobilka BK (1999) Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2- adrenergic receptors. J Biol Chem 274:16701-16708
Sica A, Saccani A, Bottazzi B, Polentarutti N., Vecchi A., van Damme J, Mantovani A. (2000). Autocrine production of IL-10 mediates defective IL-12 production and NF-κB activation in tumor-associated macrophages. J Immunol; 164: 762–767
Sorriento D, Santulli G, Del Giudice C, Anastasio A, Trimarco B, Iaccarino G (2012) Endothelial cells are able to synthesize and release catecholamines both in vitro and in vivo. Hypertension; 60:129-136
62
Hagen J, Flier JS, Lowell BB (1995) Targeted disruption of the beta 3- adrenergic receptor gene. J Biol Chem 270:29483-29492
Taddei ML, Giannoni E, Comito G, Chiarugi P (2013). Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett.; 341:80–96
Tang J, Li Z, Lu L, C CH (2013) β-adrenergic system, a backstage manipulator regulating tumor progression and drug target in cancer therapy. Semin Cancer Biol; 23:533-542
Tendler DS, Bao C, Wang T, Huang EL, Ratovitski EA, Pardoll DA, Lowenstein CJ (2001) Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis, Cancer Res. 61 3682–3688.
Vrydag W, Michel MC (2007) Tools to study beta3-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 374:385-398
Wrobel LJ, Le Gal FA (2015) Inhibition of human melanoma growth by a non- cardioselective β-blocker. J Invest Dermatol 135(2):525-31
Wuest M, Eichhorn B, Grimm MO, Wirth MP, Ravens U, Kaumann AJ (2009) Catecholamines relax detrusor through beta 2-adrenoceptors in mouse and beta 3-adrenoceptors in man. J Pharmacol Exp Ther 328:213-222